The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Volume 339:209-215 July 23, 1998 Number 4
NextNext

Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant
Allen C. Steere, M.D., Vijay K. Sikand, M.D., François Meurice, M.D., Dennis L. Parenti, M.D., Erol Fikrig, M.D., Robert T. Schoen, M.D., John Nowakowski, M.D., Christopher H. Schmid, Ph.D., Sabine Laukamp, Charles Buscarino, B.Sc., David S. Krause, M.D., for The Lyme Disease Vaccine Study Group

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
 by Steigbigel, R. T.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background The risk of acquiring Lyme disease is high in areas in which the disease is endemic, and the development of a safe and effective vaccine is therefore important.

Methods We conducted a multicenter, double-blind, randomized trial involving 10,936 subjects who lived in areas of the United States in which Lyme disease is endemic. Participants received an injection of either recombinant Borrelia burgdorferi outer-surface lipoprotein A (OspA) with adjuvant or placebo at enrollment and 1 and 12 months later. In cases of suspected Lyme disease, culture of skin lesions, polymerase-chain-reaction testing, or serologic testing was done. Serologic testing was performed 12 and 20 months after study entry to detect asymptomatic infections.

Results In the first year, after two injections, 22 subjects in the vaccine group and 43 in the placebo group contracted definite Lyme disease (P=0.009); vaccine efficacy was 49 percent (95 percent confidence interval, 15 to 69 percent). In the second year, after the third injection, 16 vaccine recipients and 66 placebo recipients contracted definite Lyme disease (P<0.001); vaccine efficacy was 76 percent (95 percent confidence interval, 58 to 86 percent). The efficacy of the vaccine in preventing asymptomatic infection was 83 percent in the first year and 100 percent in the second year. Injection of the vaccine was associated with mild-to-moderate local or systemic reactions lasting a median of three days.

Conclusions Three injections of vaccine prevented most definite cases of Lyme disease or asymptomatic B. burgdorferi infection.


Source Information

From the Division of Rheumatology and Immunology (A.C.S., V.K.S.) and Clinical Care Research (C.H.S.), Tufts University School of Medicine, New England Medical Center, Tupper Research Institute, Boston; Research and Development, SmithKline Beecham Pharmaceuticals, Collegeville, Pa. (F.M., D.L.P., C.B., D.S.K.); the Department of Medicine, Yale University School of Medicine, New Haven, Conn. (E.F., R.T.S.); the Division of Infectious Diseases, New York Medical College, Valhalla (J.N.); and Kendle/gmi, Munich, Germany (S.L.).

Address reprint requests to Dr. Steere at New England Medical Center, Box 406, 750 Washington St., Boston, MA 02111.

Full Text of this Article


Related Letters:

Immunization against Lyme Disease
Hayes E. B., Dennis D. T., Luger S., Anderson J. R., Steere A. C., Parenti D. L., Krause D. S., Sigal L. H., Zahradnik J., Weinstein A.
Extract | Full Text  
N Engl J Med 1998; 339:1637-1639, Nov 26, 1998. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.